Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases globally. The company focuses on developing product candidates for eye conditions, allergic and inflammatory diseases, cardiovascular and metabolic disorders, neurological and infectious diseases, rare diseases, and cancer. Key products include EYLEA injections for wet age-related macular degeneration and diabetic macular edema, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. Regeneron also has collaborations with Bayer for EYLEA, Alnylam for RNAi therapeutics, Intellia for CRISPR/Cas9 gene editing, Hansoh for a dual GLP-1/GIP receptor, and Tessera for a gene editing therapy for Alpha-1.

Regeneron Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol REGN. The company trades in United States Dollars (USD), as it is headquartered in the United States. Being listed on NasdaqGS provides Regeneron with access to a broad base of global investors and liquidity. The exchange is one of the world's largest stock exchanges, known for hosting many leading technology and healthcare companies. Investors can trade REGN shares during regular market hours, and the stock is also included in various indices. The currency denomination in USD makes it straightforward for U.S.-based investors, while international investors may need to consider currency exchange rates when investing.

Regeneron Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Regeneron focuses on using biological processes and living organisms to develop innovative medicines. This industry involves research and development of drugs for a wide range of diseases, often requiring significant investment in R&D and clinical trials. Regeneron's portfolio includes treatments for eye diseases, inflammatory conditions, cancer, and rare genetic disorders. The biotechnology industry is characterized by high growth potential but also high risk due to regulatory hurdles and competition. Regeneron has established itself as a key player with several approved products and a robust pipeline of candidates in various stages of development.

Regeneron's main products include EYLEA (aflibercept) injections for wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity. Dupixent (dupilumab) is approved for atopic dermatitis and asthma. Libtayo (cemiplimab) treats metastatic or locally advanced cutaneous squamous cell carcinoma. Praluent (alirocumab) is used for heterozygous familial hypercholesterolemia. Kevzara (sarilumab) treats rheumatoid arthritis. Additionally, Regeneron has a collaboration with Bayer for EYLEA 8 mg and EYLEA. The company also partners with Alnylam for RNAi therapeutics targeting eye and CNS diseases, Intellia for CRISPR/Cas9 gene editing for neurological and muscular diseases, Hansoh for a dual GLP-1/GIP receptor, and Tessera for a gene editing therapy for Alpha-1.

Regeneron generates revenue primarily through the sale of its approved medicines, which are developed internally or through collaborations. The company commercializes products directly in the United States and through partners in other regions. Key revenue drivers include EYLEA for eye diseases, Dupixent for inflammatory conditions, and Libtayo for cancer. Regeneron also earns royalties and milestone payments from licensing agreements and collaborations with companies like Bayer, Alnylam, Intellia, Hansoh, and Tessera. These partnerships often involve co-development and profit-sharing arrangements. Additionally, Regeneron invests heavily in research and development to expand its pipeline, which includes candidates for various diseases. The company's business model focuses on innovation in biotechnology, leveraging its proprietary technologies to create novel therapies and maximize long-term value through a combination of product sales and strategic alliances.